Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.

The chemical name for dofetilide is N-phenoxyl-N-methylethylamino}ethyl)phenyl" target="_blank" >^*- methanesulphonamide. It is marketed under the trade name Tikosyn^® by Pfizer, and is available in the United States in capsules containing 125, 250, and 500 µg of dofetilide. Due to the pro-arrhythmic potential of dofetilide, it is only available by prescription by physicians who have undergone specific training in the risks of treatment with dofetilide. In addition, it is only available by mail order or through specially trained local pharmacies to individuals who are prescribed dofetilide by a physician who is registered as being able to prescribe the pharmaceutical.

The elimination half-life of dofetilide is roughly 10 hours, however this is variable based on many physiologic factors (most significantly creatinine clearance), and ranges from 4.8 to 13.5 hours.

More on [ Dofetilide ]

Dofetilide - Twitter Search

Anti-arrythmic drug that should only be started in a hospital setting (ECG monitoring): dofetilide #clinicalpearl #cardiology
Beach_Rak (Beach-Rak Medicine) Sun, 23 Oct 2011 22:54:21 -0000
Anti-arrythmic drug that should only be started in a hospital setting (ECG monitoring): dofetilide #clinicalpearl #cardiology

Subscribe to Dofetilide RSS feed